SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-22-028600
Filing Date
2022-08-09
Accepted
2022-08-09 08:30:56
Documents
14
Period of Report
2022-08-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K virx-8k_20220809.htm   iXBRL 8-K 37299
2 EX-99.1 d333166dex991.htm EX-99.1 130183
3 GRAPHIC g333166logo.jpg GRAPHIC 13755
  Complete submission text file 0001564590-22-028600.txt   326069

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA virx-20220809.xsd EX-101.SCH 5569
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE virx-20220809_lab.xml EX-101.LAB 19320
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE virx-20220809_pre.xml EX-101.PRE 11471
8 EXTRACTED XBRL INSTANCE DOCUMENT virx-8k_20220809_htm.xml XML 3559
Mailing Address 2533 S COAST HWY 101 SUITE 210 CARDIFF CA 92007
Business Address 2533 S COAST HWY 101 SUITE 210 CARDIFF CA 92007 858-400-8470
Viracta Therapeutics, Inc. (Filer) CIK: 0001061027 (see all company filings)

IRS No.: 943295878 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-51531 | Film No.: 221146643
SIC: 2834 Pharmaceutical Preparations